Results 151 to 160 of about 2,152,109 (243)

Chrysin attenuates diabetes‐induced retinal injury by inhibiting microglial GBP3/NLRP3/GSDMD‐mediated pyroptosis

open access: yesAnimal Models and Experimental Medicine, EarlyView.
We investigated the therapeutic potential and mechanism of chrysin in experimental diabetic retinal disease. Using a streptozotocin (STZ)‐induced diabetic mouse model and high‐glucose‐stimulated BV2 microglia, we revealed chrysin‐responsive pyroptosis‐associated signatures and identified GBP3 as a regulated node.
Qun Liu   +9 more
wiley   +1 more source

Silk Fibroin for Cardiovascular Medical Devices: Review of Material Properties, Applications, and Clinical Potential

open access: yesAdvanced NanoBiomed Research, EarlyView.
Silk fibroin is an attractive natural biomaterial that can be engineered into diverse cardiovascular constructs, including vascular grafts, cardiac patches, heart valves, and stent coatings. Its tunable biological and mechanical properties have driven substantial preclinical progress; however, widespread clinical translation in cardiovascular ...
Mahsa Haghighattalab   +8 more
wiley   +1 more source

Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections

open access: yes, 2017
Ariana M Levin, Irene Rusu, Anton Orlin, Mrinali P Gupta, Peter Coombs, Donald J D’Amico, Szilárd Kiss Department of Ophthalmology, Weill Cornell Medical College, New York, NY, USA Purpose: The aim of this study is to report peripheral ...
Coombs P   +6 more
core  

Beyond clinical efficacy: Measuring the life impact of repeated Anti-VEGF Injections in Indian patients

open access: yes
Purpose: To evaluate the psychosocial and economic burden associated with repeated intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections in Indian patients.
Prerna Upadhyaya   +2 more
core   +1 more source

The changes in patients of diabetic maculopathy after anti-VEGF intravitreal injections

open access: yes, 2015
Diabētiskās retinopātijas (DR) biežākais redzes pasliktināšanās iemesls ir makulas tūska. Kopš 2006. gada diabētisku makulopātiju (DM) ārstē ar anti – vaskulārā endotēlija augšanas faktora inhibotoru (anti-VEGF) preparātiem un viens no tiem ir ...
Ļišņova, Alīna
core  

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy